Published in Int J Cancer on December 15, 2008
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One (2010) 1.83
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J (2012) 1.32
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One (2011) 1.15
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis (2011) 1.00
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol (2011) 1.00
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res (2012) 0.95
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol (2010) 0.91
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer (2011) 0.89
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer (2011) 0.87
Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res (2014) 0.83
Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol (2012) 0.80
Genetic and epigenetic changes in human prostate cancer. Iran Red Crescent Med J (2011) 0.79
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs (2012) 0.77
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer Cell Int (2014) 0.76
High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. J Mol Biochem (2016) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol (2008) 3.16
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res (2006) 2.82
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat (2010) 2.40
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol (2007) 2.03
Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science (2013) 1.90
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2010) 1.88
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One (2010) 1.83
Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.57
Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J Pathol (2010) 1.48
Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas (2007) 1.32
Androgen regulation of micro-RNAs in prostate cancer. Prostate (2010) 1.30
Function of ERBB4 is determined by alternative splicing. Cell Cycle (2011) 1.26
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res (2009) 1.20
Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene (2004) 1.18
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther (2005) 1.18
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget (2013) 1.14
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol (2011) 1.12
KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe (2011) 1.11
Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo. J Cell Sci (2002) 1.09
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget (2011) 1.07
Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther (2010) 1.06
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med (2012) 1.06
Impact of pre-analytical handling on bone marrow mRNA gene expression. Br J Haematol (2004) 1.02
A cell spot microarray method for production of high density siRNA transfection microarrays. BMC Genomics (2011) 0.98
Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res (2004) 0.97
GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. PLoS One (2011) 0.95
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. J Proteome Res (2011) 0.93
The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer (2011) 0.93
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia (2003) 0.92
Characterization of Diaphanous-related formin FMNL2 in human tissues. BMC Cell Biol (2010) 0.92
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One (2012) 0.91
In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol (2011) 0.90
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer Metastasis Rev (2014) 0.89
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem (2012) 0.89
c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells. Mol Cell Biol (2012) 0.89
Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget (2014) 0.89
Transcript and proteome analysis reveals reduced expression of calgranulins in head and neck squamous cell carcinoma. Eur J Cell Biol (2005) 0.88
Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia (2010) 0.88
FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion. PLoS One (2013) 0.87
Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol (2008) 0.84
Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin Cancer Res (2009) 0.84
Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. BMC Bioinformatics (2012) 0.84
Differentiation-promoting culture of competent and noncompetent keratinocytes identifies biomarkers for head and neck cancer. Am J Pathol (2011) 0.82
Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Hum Genet (2004) 0.82
Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Med (2011) 0.82
Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer (2010) 0.82
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. PLoS One (2012) 0.80
Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. Prostate (2011) 0.79
Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. Int J Cancer (2014) 0.78
VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res (2014) 0.78
Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. BioData Min (2011) 0.77
A decade of cancer gene profiling: from molecular portraits to molecular function. Methods Mol Biol (2010) 0.77
Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na. Mol Cancer Ther (2014) 0.77
Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS One (2016) 0.75
Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. PLoS One (2012) 0.75
Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. Epigenomics (2010) 0.75
Reference spectra from squamous epithelium and connective tissue allow whole section proteomics analysis. Arch Physiol Biochem (2010) 0.75
Stimulation of human embryonic stem cell-derived cardiomyocytes on thin-film microelectrodes. Biotechnol J (2011) 0.75